FDA Opened the Door on a Rare Sinus Disease. Insurers Will Decide Who Walks Through.

I was in a library once, thumbing through a dusty local-court digest, when it hit me how much of American life is decided by people you never meet using rules you never see. Not a conspiracy. A filing system. In healthcare, the filing system has a co-pay.

What the FDA did (in public, on the record)

On February 25, 2026, the Food and Drug Administration approved Dupixent (dupilumab) for adults and children ages 6 and up with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. The FDA calls it the first approval for the condition.

AFRS is not your garden-variety stuffy-nose season. The FDA describes it as an uncommon, chronic sinus inflammation driven by an allergic reaction to fungi in the sinuses, with thick, sticky mucus. It can include expansion of the sinuses and erosion of surrounding bone, and in severe cases can push toward the eye area or brain. At that point your body stops being a body and starts being a construction site.

The FDA says the approval was supported by a 52-week study in patients 6 years and older. The agency points to improvements on CT scan scoring for sinus opacification, plus improvements in measures like nasal polyp size, congestion, and sense of smell. It also highlights reduced need for systemic corticosteroids and sinus surgery compared with placebo, and notes the safety profile looked consistent with what is already known for the drug.

That is the part I can respect: the referee blew the whistle, dated the page, and made a new play legal.

The tradeoff: progress paid for with paperwork and privacy

Here is the part that never makes the celebratory press release. In modern American medicine, FDA approval is often the start of the argument, not the end. The real gate swings on coverage, prior authorization, and the fine print of “medical necessity.”

And those gates are built out of patient data. If you want a high-cost biologic, the system often wants a biography:

• Imaging
• Procedure history
• Medication history
• Symptoms translated into billing codes

The approved indication includes a history of sino-nasal surgery. That is clinically meaningful, and also administratively irresistible. It turns your chart into a passport that has to be stamped, photocopied, and re-stamped until you either get the drug or run out of time.

The Orwell check: when delay wears a lab coat

Listen to the euphemisms and you can hear the power moving: “utilization management,” “benefits determination,” “step therapy,” “site of care optimization.” Translate it and a lot of it reads: prove you are sick enough, again, to someone who will not meet you.

The FDA did its job in public. The payer side too often does its job in private, with criteria you only see after you have been denied. That is a due process problem dressed up as a customer-service issue.

The liberty ledger (who gains, who loses)

• Patients gain a new, FDA-approved option that could mean fewer surgeries or fewer courses of systemic steroids.
• Clinicians gain another tool authorized for the problem at hand, which can matter when coverage fights multiply.
• Insurers and plan administrators gain a clearer box to build policies around, for better or worse.
• The public gains the possibility of fewer repeat surgeries and complications, and inherits the bill and the temptation to ration through delay.

The approval expands the menu. The fight is whether the menu becomes a meal or just a laminated tease.

The Paine test, and the guardrails that would make this real

The Paine test is simple: does the next phase expand a patient’s practical freedom to get appropriate care, or concentrate power in the hands of whoever controls the paperwork?

• Transparency: coverage criteria should be public, plain-language, and stable.
• Speed with teeth: appeals should move on timelines that match a patient’s life; when deadlines are missed, the default should not be “wait longer.”
• Data minimization: request the narrowest slice of information necessary, not a full medical autobiography.
• Oversight: treat prior authorization and documentation demands like the quasi-judicial system they are.

The FDA did the public part. Now the rest of government should do the boring part: rules, audits, enforcement, sunlight. Because if a life-changing therapy exists on paper but not in practice, we have not solved a medical problem. We have just invented a new reason to stand in line.

So here is my question: should access to an FDA-approved treatment hinge more on clinical need, or on how much private information you are willing to surrender to prove you deserve it?